Predict your next investment

Corporation
INTERNET | Internet Software & Services / HR & Workforce Management

See what CB Insights has to offer

Stage

Acquired | Acquired

Valuation

$0000 

About Cytiva

Cytiva was one of the first companies to develop an online job board focusing on the tech sector. They also developed SonicRecruit, a web-based solution that automated the entire recruiting process and provided an applicant tracking system. Cytiva also has solutions for onboarding and performance management.In 2011, Cytiva was acquired by Taleo.

Cytiva Headquarter Location

4089 Emery Street

Emeryville, California, 94608,

United States

Latest Cytiva News

Cytiva pledges $52.5M into South Korean operations as it expands global plans

Sep 30, 2021

Josh Sullivan Associate Editor When Cytiva decided it would play a role in the Covid-19 pandemic, it moved quickly to open new manufacturing sites and adapt existing ones. Now, the company will send that investment overseas as the company announced a multimillion-dollar memorandum of understanding with South Korea last week. South Korean President Moon Jae-in was present for the announcement, which took place at a New York ceremony. Cytiva has pledged $52.5 million in South Korea for the next two years, starting in 2022, Moon said. Keep reading Endpoints with a free subscription Unlock this story instantly and join 118,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle Blankenship Managing Editor GlaxoSmithKline’s R&D head Hal Barron has spent his four years on the job taking swing after swing to rejuvenate the drug giant’s pipeline after years of inertia. One of Barron’s biggest swings has now blown up in his face after a key cancer drug went down in flames in the clinic. GSK and Merck KGaA have ended their $4 billion collaboration on bintrafusp alfa, a once-promising cancer drug and the crown jewel of Barron’s pipeline rebuild efforts that has endured a spate of failures in recent months, the companies said Thursday. Keep reading Endpoints with a free subscription Unlock this story instantly and join 118,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle Blankenship Managing Editor Confirming days of rumors and insider leaks , Merck will acquire Acceleron Pharma and its lead PAH drug sotatercept for $11.5 billion, the companies said Thursday. The acquisition doesn’t come at much of a premium: Shares of $XLRN closed Wednesday at around $175, suspiciously plummeting from a high of around $186 earlier in the day. The company’s stock had ticked up for days after reports from Bloomberg and the Wall Street Journal quoting insider sources mostly outlined the terms of the deal with Merck. Keep reading Endpoints with a free subscription Unlock this story instantly and join 118,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Josh Sullivan Associate Editor Amidst heavy demand for drugs and vaccines throughout the world, a new House bill, dubbed the PREPARE ACT of 2021, would create a national stockpile of active pharmaceutical ingredients and prevent supply chain shortages. The bill, introduced by Rep. Abigail Spanberger, D-Va., and Rep. David McKinley, R-WV, would ensure the country has a stockpile of APIs needed to manufacture generics for a list of essential medicines that would be determined by a group that includes the FDA commissioner, the assistant secretary for preparedness and response and the secretary of defense. The FDA commissioner has already identified a list as of Oct. 30, which would be updated at least once a year. Read More Amber Tong Senior Editor Marc Dunoyer has unveiled his first buyout since taking over at Alexion — one that his predecessors have lassoed in before a $39 billion merger made the rare disease specialist a part of AstraZeneca. The deal adds another drug to Alexion’s late-stage pipeline, which is heavily populated by candidates sourced through M&A and licensing pacts. It also takes AstraZeneca into a risky disease that has blown up efforts by Prothena and GlaxoSmithKline. Keep reading Endpoints with a free subscription Unlock this story instantly and join 118,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cytiva

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cytiva is included in 1 Expert Collection, including HR Tech.

H

HR Tech

3,964 items

HR tech startups are helping companies manage critical pain points in HR processes such as recruitment, automation, career development, compensation, and benefits management, through a mix of software and services.

Cytiva Patents

Cytiva has filed 86 patents.

The 3 most popular patent topics include:

  • Chromatography
  • Molecular biology
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/6/2017

11/23/2021

Polymers, Copolymers, Elastomers, Polymer chemistry, Analytical chemistry

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/6/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/23/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Polymers, Copolymers, Elastomers, Polymer chemistry, Analytical chemistry

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.